Abstract 482P
Background
HER2-low metastatic breast cancer (mBC) is a clinically relevant subgroup with promising treatment options. Challenges relate to establishing HER2-low status when biopsies are not feasible, and little is known about disease heterogeneity. PET-imaging with a HER2-specific tracer could shed light on these issues.
Methods
At the Karolinska Comprehensive Cancer Center in Stockholm, Sweden we conducted a proof-of-concept prospective imaging study with the [68Ga]Ga-ABY-025 tracer in patients with mBC with a previous HER2-low tumor biopsy, who were scheduled for a new line of systemic therapy. A HER2-PET and tumor biopsy (immunohistochemistry [IHC] and in situ hybridization [ISH]) were performed. The study was funded by the Swedish Breast Cancer Society and Stockholm’s Region.
Results
Seventeen patients were informed, ten patients provided written consent and in ten, paired PET and biopsy results are available (Table). No unexpected side effects were noted. In all, HER2-PET revealed areas with [68Ga]Ga-ABY-025 maximal Standardized Uptake Value (SUVmax) higher than background ratio. HER2-low status was confirmed in tumor biopsies in eight, whereas two patients had HER2 0 in a tumor lesion that was avid on HER2-PET. Substantial heterogeneity was observed in [68Ga]Ga-ABY-025 uptake between different lesions within the same patient. Table: 482P
Pat ID | HER2-PET | Biopsy | |||||||
Metastases | SUVmax tumor | SUVmax spleen | SUVmax liver * | SUVmax myocardium (left chamber) | Site | ER/PR/Ki67 | HER2 IHC biopsy | HER2/C17 gene amplification quote | |
1 | Liver | 12.9 | 2.6 | 9.1 | 3.1 | Liver | 100/100/19 | IHC 1+ | 2.85/1.02.85 |
2 | Bone and lymph nodes | 6.1 | 3.9 | 13.7 | 4.4 | Lymph node | 0/0/95 | IHC 1+ | - |
3 | Liver | 28.7 | 3.0 | n.a. | 4.1 | Liver | 80/70/x | IHC 2+ | 3.3/2.31.4 |
4 | Bone and liver | 10.7 | 5.0 | n.a. | 3.2 | Liver | 80/70/78 | IHC 1+ | 4.4/2.51.76 |
5 | Bone and liver | 24.9 | 3.9 | 13.4 | 4.1 | Liver | 30/0/60 | IHC 0 | - |
6 | Bone, skin, liver | 3.7 | 2.8 | n.a. | 3.1 | Skin | 0/0/39 | IHC 0 | - |
7 | Breast, brain | 10.3 | 2.3 | 13.8 | 3.8 | Breast | 60/0/40 | IHC 2+ | 3.6/1.452.48 |
8 | Liver | 33.4 | 2.7 | 13.3 | 4.1 | Liver | 95/0/3 | IHC 2+ | 1.3/1.80.7 |
9 | Bone, liver | 19.0 | 3.0 | n.a. | 3.7 | Liver | 95/95/13 | IHC 2+ | 2.25/1.551.45 |
10 | Liver, bone | 12.0 | 2.7 | n.a | 2.7 | Liver | 0/0/33 | IHC 2+ | 2.65/1.351.96 |
* measured on healthy liver tissue
Conclusions
The visualization of HER2-expressing mBC with [68Ga]Ga-ABY-025 PET/CT is feasible and safe. An intriguing finding is the fact that we noted tracer uptake in lesions that are HER2 0. A continued study is planned where patients with HER2-low mBC are selected for HER2-antibody drug conjugate based on HER2-status on PET and/or IHC.
Clinical trial identification
NCT05619016 EU CT 2022-500448-39-00.
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University Hospital/Region Stockholm.
Funding
Grants from the Swedish government under the ALF-agreement (SLL20200025), Sjöberg Foundation (929649), and the Swedish Breast Cancer Society (190850).
Disclosure
N. Brun, F. Y. Frejd: Financial Interests, Personal, Full or part-time Employment: Affibody AB; Financial Interests, Personal, Leadership Role: Affibody AB; Financial Interests, Personal, Ownership Interest: Affibody AB. T.A. Tran: Financial Interests, Personal, Stocks or ownership: Diaprost; Financial Interests, Personal, Research Funding: Affibody AB; Financial Interests, Personal, Royalties: Diaprost. All other authors have declared no conflicts of interest.
Resources from the same session
466P - Integrated analysis of potential prognosis and differential expression between primary and metastatic foci for COL12A1 in breast cancer
Presenter: Lei Tang
Session: Poster session 04
467P - Initial results from the Canarian registry of luminal breast cancer patients treated with first-line CDK 4/6 inhibitors
Presenter: Isaac Ceballos Lenza
Session: Poster session 04
468P - Impact of low HER2 status on CDK4/6 inhibitor and endocrine therapy in metastatic HR+ breast cancer: A retrospective multicenter study
Presenter: Eda Caliskan Yildirim
Session: Poster session 04
469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment
Presenter: Maria Torrente
Session: Poster session 04
470P - Increased risk of vertebral fractures in healthy bone in metastatic breast cancer patients treated with CDK4/6 inhibitors combined with endocrine therapy
Presenter: Marco Bergamini
Session: Poster session 04
471P - Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
Presenter: Chiara Paratore
Session: Poster session 04
472P - Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
Presenter: Joshua Tobias
Session: Poster session 04
473P - Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors
Presenter: Kreina Vega Cano
Session: Poster session 04
474P - ctDNA-based copy number dynamics during anti-PD1 treatment in patients with metastatic triple-negative breast cancer
Presenter: Aaron Lin
Session: Poster session 04
475P - Dynamics of TROP2 expression in triple-negative breast cancer
Presenter: Ana C Garrido-Castro
Session: Poster session 04